**Core Concept**
Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist used in the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). It is a key component in the management of CINV, particularly in patients receiving highly emetogenic chemotherapy.

**Why the Correct Answer is Right**
Aprepitant acts by blocking the action of substance P at the NK1 receptors in the central nervous system, thereby inhibiting the emetic signal transmission in the area postrema. This action reduces the risk of nausea and vomiting in patients undergoing chemotherapy. Aprepitant is often used in combination with other antiemetics, such as 5-HT3 antagonists and corticosteroids, to provide effective protection against CINV.

**Why Each Wrong Option is Incorrect**
**Option A:** Aprepitant is not a dopamine antagonist; it works through a different mechanism to prevent CINV.

**Option B:** Aprepitant is not metabolized by the cytochrome P450 3A4 enzyme; it is actually metabolized by CYP3A4, but its primary route of elimination is through the kidneys.

**Option C:** Aprepitant is not a selective serotonin reuptake inhibitor; it does not affect serotonin levels in the brain.

**Option D:** Aprepitant is not a corticosteroid; it is a distinct class of medication used to prevent CINV.

**Clinical Pearl / High-Yield Fact**
Aprepitant is often used in combination with other antiemetics to provide effective protection against CINV, particularly in patients receiving highly emetogenic chemotherapy. It is essential to consider the emetogenic potential of the chemotherapy regimen when selecting antiemetic therapy.

**Correct Answer: D. Aprepitant is not a corticosteroid; it is a distinct class of medication used to prevent CINV.**